Andrew J. Einhorn - 23 Dec 2025 Form 4 Insider Report for Pelthos Therapeutics Inc. (CHRO)

Reporting relationship: Director
Issuer ticker: CHRO
Reported as of: 23 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Dec 2025, 16:16:56 UTC
Prior SEC filing: 15 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Andrew J. Einhorn

Key filing fact

Andrew J. Einhorn filed Form 4 for Pelthos Therapeutics Inc. (CHRO) on 29 Dec 2025.

Key facts

This page summarizes Andrew J. Einhorn's Form 4 filing for Pelthos Therapeutics Inc. (CHRO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Dec 2025, 16:16.

Change

Previous filing in this sequence was filed on 15 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001560685 Primary reporting owner

Einhorn Andrew J.

Relationship: Director
Address: C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM
Signature: /s/ Andrew J. Einhorn
Signature date: 29 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTHS transaction

Common Stock

Award

Transaction value
Shares: +12,000
Change %
Price
Shares after: 12,000
Date: 23 Dec 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the "RSUs") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the "Plan"). The RSUs will vest on January 1, 2027. Each RSU represents a contingent right to receive one share of issuer's Common Stock, par value $0.0001 per share.